Latest news with #RichardM.Goldberg
Business Wire
a day ago
- Business
- Business Wire
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. ('Agenus' or the 'Company') (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; together they are designed to trigger robust and durable immune attacks against 'cold,' treatment-resistant tumors, offering new hope where standard therapies have failed. 'Our team is committed to advancing BOT/BAL to deliver meaningful benefits to patients with treatment-resistant cancers, and we are working with regulatory agencies to expedite access through a streamlined Phase 3 trial,' said Garo Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. 'With significant clinical progress, strategic partnerships, and prudent financial management, we are well-positioned to execute our vision of transforming cancer care.' Regulatory Highlights Breakthrough Survival in Refractory MSS CRC – At the 2025 ESMO Gastrointestinal Cancers Congress, BOT + BAL reported a 42% two-year survival rate and median overall survival of ~21 months in a trial of 123 patients with refractory no liver met MSS metastatic colorectal cancer (mCRC). Regulatory Alignment on Registrational Phase 3 Trial (BATTMAN) – Following an End-of-Phase 2 meeting on July 1, 2025, the FDA agreed to a streamlined two-arm BATTMAN Phase 3 design, having agreed to BOT/BAL's contribution of components. This agreement also marks a shift from a three-arm trial previously proposed by regulators and enables trial initiation in Q4 2025. Expanding Evidence Across Tumor Types – New data from a neoadjuvant pan-cancer trial (NEOASIS study) showed robust pathological responses across MSS and MSI-H solid tumors, including triple-negative breast cancer, with no dose-limiting toxicities. Translational data from ASCO confirmed BOT/BAL's ability to activate T cells and address resistance in MSS tumors, supporting its potential across cancers. 'The BOT/BAL combination is delivering durable responses and survival outcomes in refractory MSS colorectal cancer,' said Richard M. Goldberg, M.D., Chief Development Officer of Agenus. 'With regulatory clarity and a focused development team, we are poised to execute the BATTMAN trial and explore earlier treatment settings to maximize patient impact.' Strategic Partnerships Zydus Lifesciences Collaboration – The collaboration for U.S. manufacturing and commercialization in India/Sri Lanka is progressing toward a Q3 2025 closing, delivering $91M in upfront capital and equity investment upon closing to support development and regulatory activities. Noetik AI Biomarker Collaboration using AI algorithms – Agenus commenced a partnership with Noetik AI to refine patient selection, enhancing BOT/BAL's clinical impact and unlocking potential future revenue streams through precision oncology. Broader Portfolio Synergies – Agenus continues to leverage its significant ownership of MiNK Therapeutics and SaponiQx, to advance combination treatments with adoptive cell therapies and adjuvants, broadening its immuno-oncology pipeline. Key 2H 2025 Catalysts— Building on recent clinical, regulatory, and partnership momentum, Agenus anticipates several significant milestones in the second half of 2025: Registrational Trial Launch – In Q4 2025, initiate the global BATTMAN Phase 3 trial of BOT/BAL in refractory MSS CRC in partnership with the Canadian Clinical Trials Group (CCTG), committed to executing with speed and precision. Significant Clinical Data Generation – Expand evidence for BOT/BAL's activity in earlier-line and neoadjuvant MSS colorectal cancer and other tumors through strategic collaborations and investigator-sponsored trials. Upcoming Data Presentations – Share new BOT/BAL clinical results in colorectal and other solid tumors at major oncology congresses in Q4 2025, reinforcing its therapeutic potential. Financial Highlights— Agenus continues to strengthen its financial position through prudent cost management and strategic capital-raising efforts in addition to Zydus collaboration, positioning the company to execute its clinical and regulatory objectives. Key financial metrics for Q2 2025 are summarized below: Revenue and Net Loss – Agenus reported revenue of $25.7 million for Q2 2025 and $49.8 million for Q2 YTD 2025, primarily from non-cash royalty revenue, compared to $51.5 million in Q2 YTD 2024. The net loss Q2 YTD 2025 was $56.4 million, or $2.03 per share, a significant improvement from $118.3 million, or $5.56 per share, for Q2 YTD 2024. Reduced Cash Burn – Cash used in operations decreased to $45.8 million for Q2 YTD 2025 from $76.4 million for Q2 YTD 2024. These reductions are a consequence of prudent cost management and are expected to continue into the second half of 2025. Agenus is also in active negotiations for collaborations that could result in additional significant infusions of cash resources. Liquidity and Future Outlook – With the $91 million Zydus infusion expected upon closing, combined with its current cash balance, Agenus expects to fund the launch of its Phase 3 trial. Further, the company is in negotiations to secure additional funding streams from partnerships currently under negotiation and BOT/BAL's commercial prospects in geographies beyond North America, Europe and Japan. Webcast and Conference Call Information The Company will host a webcast and Stakeholder Briefing on August 27, 2025, to review Q2 financial results, anticipated data milestones, and the global BOT/BAL development program. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. Founded in 1994, Agenus is advancing antibody therapeutics, adoptive cell therapies through MiNK Therapeutics, and adjuvants through SaponiQx, leveraging robust end-to-end development capabilities, including commercial and clinical cGMP manufacturing facilities and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Agenus' Commitment to Patient Access Agenus is dedicated to making investigational medicines available to patients with cancer at the appropriate time and in the correct manner. For more information, visit About Botensilimab (BOT) Botensilimab (AGEN1181) is a next-generation, multifunctional, Fc-enhanced CTLA-4 antibody engineered to boost both innate and adaptive anti-tumor immune responses. Its unique design aims to overcome the limitations of first-generation CTLA-4 inhibitors (like ipilimumab) and extend immunotherapy benefits to 'cold' tumors that typically respond poorly or not at all to standard immune checkpoint blockade. Botensilimab's Fc-enhanced structure allows it to robustly engage activating Fc receptors on key immune cells, thereby priming and activating T cells, depleting immunosuppressive regulatory T cells in the tumor microenvironment, activating myeloid cells, and inducing long-term immune memory. Through these mechanisms, botensilimab has demonstrated the ability to ignite immune responses across a range of solid tumors, including those resistant to conventional PD-1 or CTLA-4 therapies. To date, approximately 1,200 patients have been treated with botensilimab and/or balstilimab in Phase 1 and 2 trials. Botensilimab alone or in combination with Agenus' investigational PD-1 antibody balstilimab has shown clinical responses in nine different metastatic cancers in late-line settings. For more information on ongoing botensilimab trials, please visit About Balstilimab (BAL) Balstilimab (AGEN2034) is a novel, fully human monoclonal IgG4 antibody that blocks PD-1 (programmed cell death-1) from interacting with its ligands PD-L1 and PD-L2. By inhibiting the PD-1 checkpoint pathway, balstilimab aims to restore T-cell activity against tumors. It has been evaluated in over 900 patients to date and has demonstrated clinical activity with a favorable tolerability profile in several tumor types. Balstilimab is being studied both as a monotherapy and in combination with other agents (such as botensilimab) to expand its therapeutic impact. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the botensilimab and balstilimab clinical programs, expected trial initiations, regulatory plans, and potential benefits of the combination therapy. These statements are subject to risks and uncertainties described in Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Agenus cautions investors not to place undue reliance on these statements, which speak only as of the date of this announcement. The company undertakes no obligation to update or revise these statements, except as required by law.
Associated Press
12-05-2025
- Business
- Associated Press
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
LEXINGTON, Mass.--(BUSINESS WIRE)--May 12, 2025-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage global health authorities. Dr. Goldberg's distinguished career spans over four decades, during which he has made significant contributions to oncology through clinical practice, research, and leadership. 'Five years ago, I stepped away from formal cancer center leadership roles in academic oncology and from clinical practice. That afforded me time to apply my skills differently by advising companies developing new drugs and technologies for treating GI cancers and particularly colorectal cancer. I also used this opportunity to become even more actively engaged in patient advocacy. Despite incremental treatment advances, patients, and their family members, clamor daily for new and better treatments. They want more time, better time, and ultimately curative interventions where no cure is possible today. This unmet need is particularly hard felt among those with MSS colorectal cancer where the treatment benefits for immuno-oncology interventions largely remain to be realized,' said Dr. Richard Goldberg. Goldberg continues, 'As a consultant, I recognized what Agenus is achieving with botensilimab and balstilimab. This innovative combination is among the most promising approaches on the horizon. The opportunity to move these investigational agents forward to gain FDA approval and allow oncologists to integrate them into our treatment armamentarium as soon as possible compels me to recommit myself fully to the workplace. I believe these two agents can and will change outcomes for patients with colorectal cancer and, beyond that, will prove to be important tools across a broad spectrum of solid tumors.' Throughout his career, Dr. Goldberg has held several prominent positions, including: Dr. Goldberg's research has been pivotal in advancing GI oncology, with a focus on developing new treatments, understanding inherited cancer susceptibility, and identifying predictive and prognostic factors in GI cancers. He has authored over 430 peer-reviewed publications, underscoring his commitment to scientific advancement. 1 In recognition of his expertise, Dr. Goldberg has been listed in The Best Doctors in America and has received numerous accolades, including the American Society of Clinical Oncology (ASCO) Statesman Award multiple Advocacy awards and being designated as a Fellow of both ASCO and the American College of Physicians. 1 Even after his retirement, Dr. Goldberg continued to contribute to the field as a medical consultant, engaging with both start-up and established pharmaceutical companies on drug development in gastrointestinal cancers. He also remains the Associate Group Chair of the NCI funded clinical trials group the Alliance. 'Dr. Goldberg's appointment as Chief Development Officer brings unparalleled expertise in gastrointestinal oncology and a lifelong commitment to advancing patient care that align directly with our mission. As we work to bring BOT/BAL to patients in need, his strategic guidance will be instrumental in navigating the clinical and developmental complexities ahead.'— Garo Armen Ph.D., Chief Executive Officer, Agenus About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words 'may,' 'believes,' 'expects,' 'anticipates,' 'hopes,' 'intends,' 'plans,' 'forecasts,' 'estimates,' 'will,' 'establish,' 'potential,' 'superiority,' 'best in class,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Inducement Grant Disclosure In connection with Dr. Goldberg's appointment as Chief Development Officer, the Compensation Committee of Agenus' Board of Directors approved the grant of an inducement equity award under the company's 2015 Inducement Equity Plan and pursuant to Nasdaq Listing Rule 5635(c)(4). The award to Dr. Goldberg consists of options to purchase 50,000 shares of Agenus common stock, with an exercise price equal to the closing price of Agenus common stock on the grant date, May 12, 2025. The options have a 10-year term and vest immediately. 1https:// View source version on CONTACT: Investors 917-362-1370 [email protected] Media 781-674-4422 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH MEDICAL DEVICES CLINICAL TRIALS SOURCE: Agenus Inc. Copyright Business Wire 2025. PUB: 05/12/2025 07:20 AM/DISC: 05/12/2025 07:21 AM
Business Wire
12-05-2025
- Business
- Business Wire
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage global health authorities. "As a consultant, I recognized what Agenus is achieving with botensilimab and balstilimab. This innovative combination is among the most promising approaches on the horizon..." Share Dr. Goldberg's distinguished career spans over four decades, during which he has made significant contributions to oncology through clinical practice, research, and leadership. 'Five years ago, I stepped away from formal cancer center leadership roles in academic oncology and from clinical practice. That afforded me time to apply my skills differently by advising companies developing new drugs and technologies for treating GI cancers and particularly colorectal cancer. I also used this opportunity to become even more actively engaged in patient advocacy. Despite incremental treatment advances, patients, and their family members, clamor daily for new and better treatments. They want more time, better time, and ultimately curative interventions where no cure is possible today. This unmet need is particularly hard felt among those with MSS colorectal cancer where the treatment benefits for immuno-oncology interventions largely remain to be realized,' said Dr. Richard Goldberg. Goldberg continues, 'As a consultant, I recognized what Agenus is achieving with botensilimab and balstilimab. This innovative combination is among the most promising approaches on the horizon. The opportunity to move these investigational agents forward to gain FDA approval and allow oncologists to integrate them into our treatment armamentarium as soon as possible compels me to recommit myself fully to the workplace. I believe these two agents can and will change outcomes for patients with colorectal cancer and, beyond that, will prove to be important tools across a broad spectrum of solid tumors.' Throughout his career, Dr. Goldberg has held several prominent positions, including: Director of the West Virginia University Cancer Institute (WVUCI): From 2017 until his retirement in January 2020, Dr. Goldberg led WVUCI, overseeing its clinical, research, and teaching missions. Physician-in-Chief at The Ohio State University's James Cancer Hospital: Prior to his tenure at WVUCI, he served as Physician-in-Chief and Associate Director of Outreach for The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Physician-in-Chief at the North Carolina Cancer Hospital: At the University of North Carolina in Chapel Hill, Dr. Goldberg was Physician-in-Chief and Associate Director at the UNC Lineberger Comprehensive Cancer Center. Dr. Goldberg's research has been pivotal in advancing GI oncology, with a focus on developing new treatments, understanding inherited cancer susceptibility, and identifying predictive and prognostic factors in GI cancers. He has authored over 430 peer-reviewed publications, underscoring his commitment to scientific advancement. 1 In recognition of his expertise, Dr. Goldberg has been listed in The Best Doctors in America and has received numerous accolades, including the American Society of Clinical Oncology (ASCO) Statesman Award multiple Advocacy awards and being designated as a Fellow of both ASCO and the American College of Physicians. 1 Even after his retirement, Dr. Goldberg continued to contribute to the field as a medical consultant, engaging with both start-up and established pharmaceutical companies on drug development in gastrointestinal cancers. He also remains the Associate Group Chair of the NCI funded clinical trials group the Alliance. 'Dr. Goldberg's appointment as Chief Development Officer brings unparalleled expertise in gastrointestinal oncology and a lifelong commitment to advancing patient care that align directly with our mission. As we work to bring BOT/BAL to patients in need, his strategic guidance will be instrumental in navigating the clinical and developmental complexities ahead.'— Garo Armen Ph.D., Chief Executive Officer, Agenus About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to 'cold' tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," 'establish,' 'potential,' 'superiority,' 'best in class,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Inducement Grant Disclosure In connection with Dr. Goldberg's appointment as Chief Development Officer, the Compensation Committee of Agenus' Board of Directors approved the grant of an inducement equity award under the company's 2015 Inducement Equity Plan and pursuant to Nasdaq Listing Rule 5635(c)(4). The award to Dr. Goldberg consists of options to purchase 50,000 shares of Agenus common stock, with an exercise price equal to the closing price of Agenus common stock on the grant date, May 12, 2025. The options have a 10-year term and vest immediately.
Yahoo
12-05-2025
- Business
- Yahoo
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
LEXINGTON, Mass., May 12, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage global health authorities. Dr. Goldberg's distinguished career spans over four decades, during which he has made significant contributions to oncology through clinical practice, research, and leadership. "Five years ago, I stepped away from formal cancer center leadership roles in academic oncology and from clinical practice. That afforded me time to apply my skills differently by advising companies developing new drugs and technologies for treating GI cancers and particularly colorectal cancer. I also used this opportunity to become even more actively engaged in patient advocacy. Despite incremental treatment advances, patients, and their family members, clamor daily for new and better treatments. They want more time, better time, and ultimately curative interventions where no cure is possible today. This unmet need is particularly hard felt among those with MSS colorectal cancer where the treatment benefits for immuno-oncology interventions largely remain to be realized," said Dr. Richard Goldberg. Goldberg continues, "As a consultant, I recognized what Agenus is achieving with botensilimab and balstilimab. This innovative combination is among the most promising approaches on the horizon. The opportunity to move these investigational agents forward to gain FDA approval and allow oncologists to integrate them into our treatment armamentarium as soon as possible compels me to recommit myself fully to the workplace. I believe these two agents can and will change outcomes for patients with colorectal cancer and, beyond that, will prove to be important tools across a broad spectrum of solid tumors." Throughout his career, Dr. Goldberg has held several prominent positions, including: Director of the West Virginia University Cancer Institute (WVUCI): From 2017 until his retirement in January 2020, Dr. Goldberg led WVUCI, overseeing its clinical, research, and teaching missions. Physician-in-Chief at The Ohio State University's James Cancer Hospital: Prior to his tenure at WVUCI, he served as Physician-in-Chief and Associate Director of Outreach for The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Physician-in-Chief at the North Carolina Cancer Hospital: At the University of North Carolina in Chapel Hill, Dr. Goldberg was Physician-in-Chief and Associate Director at the UNC Lineberger Comprehensive Cancer Center. Dr. Goldberg's research has been pivotal in advancing GI oncology, with a focus on developing new treatments, understanding inherited cancer susceptibility, and identifying predictive and prognostic factors in GI cancers. He has authored over 430 peer-reviewed publications, underscoring his commitment to scientific advancement. 1 In recognition of his expertise, Dr. Goldberg has been listed in The Best Doctors in America and has received numerous accolades, including the American Society of Clinical Oncology (ASCO) Statesman Award multiple Advocacy awards and being designated as a Fellow of both ASCO and the American College of Physicians.1 Even after his retirement, Dr. Goldberg continued to contribute to the field as a medical consultant, engaging with both start-up and established pharmaceutical companies on drug development in gastrointestinal cancers. He also remains the Associate Group Chair of the NCI funded clinical trials group the Alliance. "Dr. Goldberg's appointment as Chief Development Officer brings unparalleled expertise in gastrointestinal oncology and a lifelong commitment to advancing patient care that align directly with our mission. As we work to bring BOT/BAL to patients in need, his strategic guidance will be instrumental in navigating the clinical and developmental complexities ahead."—Garo Armen Ph.D., Chief Executive Officer, Agenus About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus' investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," "establish," "potential," "superiority," "best in class," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Inducement Grant Disclosure In connection with Dr. Goldberg's appointment as Chief Development Officer, the Compensation Committee of Agenus' Board of Directors approved the grant of an inducement equity award under the company's 2015 Inducement Equity Plan and pursuant to Nasdaq Listing Rule 5635(c)(4). The award to Dr. Goldberg consists of options to purchase 50,000 shares of Agenus common stock, with an exercise price equal to the closing price of Agenus common stock on the grant date, May 12, 2025. The options have a 10-year term and vest immediately. 1 View source version on Contacts Investors 917-362-1370investor@ Media 781-674-4422communications@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
